Applicant	Tradename	Generic Name	NDA	Approval Date	Type	RLD	Patent Number	Product	Substance	Patent Expiration	Exclusivity Expiration
Bristol Myers Squibb	REYATAZ	atazanavir sulfate	021567	Jun 20, 2003	RX	No					Mar 25, 2011
Bristol Myers Squibb	REYATAZ	atazanavir sulfate	021567	Jun 20, 2003	RX	No					Sep 30, 2011
Bristol Myers Squibb	REYATAZ	atazanavir sulfate	021567	Jun 20, 2003	RX	No	5,849,911	Y	Y	Jun 20, 2017

Export available with Ultimate Plan subscription:

This preview shows a limited data set. Complete access is available with a Subscription

Paragraph IV activity for: REYATAZ

Drugname	Dosage	Strength	RLD	Submissiondate
atazanavir sulfate	Capsules	200 mg	Reyataz	2/16/2010
atazanavir sulfate	Capsules	100 mg and 150 mg	Reyataz	3/19/2010
atazanavir sulfate	Capsules	300 mg	Reyataz	7/20/2009

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:
2000 2001 2002 2003 2004
2005 2006 2007 2008 2009

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Follow DrugPatentWatch on Twitter

Bookmark or Share This Page ...